Michael Chrisofos

Prof. Michael Chrisofos


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Urology
Verified
Journal Article
Closed access
CDCharalambos Deliveliotis
Charalambos Deliveliotis
MCMichael Chrisofos
Michael Chrisofos
EGEvagelos Gougousis
Evagelos Gougousis
APAthanasios Papatsoris
Athanasios Papatsoris
ADAthanasios Dellis
Athanasios Dellis
IVIoannis M. Varkarakis
Ioannis M. Varkarakis

8 August 2012 in Critical Care
Verified
Journal Article
Open access
PDF file
EGEvangelos J Giamarellos-Bourboulis
Evangelos J Giamarellos-Bourboulis
ATAnna Norrby Teglund
Anna Norrby Teglund
VMVassiliki Mylona
Vassiliki Mylona
ASAthina Savva
Athina Savva
Iraklis TsangarisIraklis Tsangaris
Iraklis Tsangaris
George DimopoulosGeorge Dimopoulos
George Dimopoulos
Introduction: Early risk assessment is the mainstay of management of patients with sepsis. APACHE II is the gold standard prognostic stratification system. A prediction rule that aimed to improve prognostication by APACHE II with the application of serum suPAR (soluble urokinase plasminogen activator receptor) is developed. Methods: A prospective study cohort enrolled 1914 patients with sepsis including 62.2% with sepsis and 37.8% with severe sepsis/septic shock. Serum suPAR was measured in samples drawn after diagnosis by an enzyme-immunoabsorbent assay; in 367 patients sequential measurements were performed. After ROC analysis and multivariate logistic regression analysis a prediction rule for risk was developed. The rule was validated in a double-blind fashion by an independent confirmation cohort of 196 sepsis patients, predominantly severe sepsis/septic shock patients, from Sweden. Results: Serum suPAR remained stable within survivors and non-survivors for 10 days. Regression analysis showed that APACHE II ≥17 and suPAR ≥12 ng/ml were independently associated with unfavorable outcome. Four strata of risk were identified: i) APACHE II <17 and suPAR <12 ng/ml with mortality 5.5%; ii) APACHE II < 17 and suPAR ≥12 ng/ml with mortality 17.4%; iii) APACHE II ≥ 17 and suPAR <12 ng/ml with mortality 37.4%; and iv) APACHE II ≥17 and suPAR ≥12 ng/ml with mortality 51.7%. This prediction rule was confirmed by the Swedish cohort. Conclusions: A novel prediction rule with four levels of risk in sepsis based on APACHE II score and serum suPAR is proposed. Prognostication by this rule is confirmed by an independent cohort.

Verified
Journal Article
Open access
PDF file
Aris KaltsasAris Kaltsas
Aris Kaltsas
AZAthanasios Zikopoulos
Athanasios Zikopoulos
Fotios DimitriadisFotios Dimitriadis
Fotios Dimitriadis
DSDanja Sheshi
Danja Sheshi
MPMagdalena Politis
Magdalena Politis
ATHANASIOS ZACHARIOUATHANASIOS ZACHARIOU
ATHANASIOS ZACHARIOU
Erectile dysfunction (ED) is a prevalent condition affecting men’s sexual health, with oxidative stress (OS) having recently been identified as a significant contributing causative factor. This narrative review aims to elucidate the role of OS in the pathophysiology of ED, focusing on impact, mechanisms, and potential therapeutic interventions. Key findings indicate that OS disrupts endothelial function and nitric oxide (NO) signaling, crucial for erectile function. Various sources of reactive oxygen species (ROS) and their detrimental effects on penile tissue are discussed, including aging, diabetes mellitus, hypertension, hyperlipidemia, smoking, obesity, alcohol consumption, psychological stress, hyperhomocysteinemia, chronic kidney disease, and sickle cell disease. Major sources of ROS, such as NADPH oxidase, xanthine oxidase, uncoupled endothelial NO synthase (eNOS), and mitochondrial electron transport, are identified. NO is scavenged by these ROS, leading to endothelial dysfunction characterized by reduced NO availability, impaired vasodilation, increased vascular tone, and inflammation. This ultimately results in ED due to decreased blood flow to penile tissue and the inability to achieve or maintain an erection. Furthermore, ROS impact the transmission of nitrergic neurotransmitters by causing the death of nitrergic neurons and reducing the signaling of neuronal NO synthase (nNOS), exacerbating ED. Therapeutic approaches targeting OS, including antioxidants and lifestyle modifications, show promise in ameliorating ED symptoms. The review underscores the need for further research to develop effective treatments, emphasizing the interplay between OS and vascular health in ED. Integrating pharmacological and non-pharmacological strategies could enhance clinical outcomes for ED patients, advocating for OS management in ED treatment protocols to improve patient quality of life.

1 October 2000 in BJU International
Verified
Journal Article
Closed access
PDF file
SMS.A. Mcneill
S.A. Mcneill
MCMichael Chrisofos
Michael Chrisofos
DTD.A. Tolley
D.A. Tolley

31 August 2005 in Urology
Verified
Journal Article
Closed access
CDC. Deliveliotis
C. Deliveliotis
APA. Papatsoris
A. Papatsoris
MCMichael Chrisofos
Michael Chrisofos
ADA. Dellis
A. Dellis
CLC. Liakouras
C. Liakouras
ASA. Skolarikos
A. Skolarikos

29 May 2018 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
DSDimitrios Sinapidis
Dimitrios Sinapidis
VKVassileios Kosmas
Vassileios Kosmas
VVVasileios Vittoros
Vasileios Vittoros
IKIOANNIS KOUTELIDAKIS
IOANNIS KOUTELIDAKIS
APAikaterini Pantazi
Aikaterini Pantazi
EGEvangelos J Giamarellos-Bourboulis
Evangelos J Giamarellos-Bourboulis
Development of sepsis is a process with significant variation among individuals. The precise elements of this variation need to be defined. This study was designed to define the way in which comorbidities contribute to sepsis development. Three thousand five hundred nine patients with acute pyelonephritis (AP), community-acquired pneumonia (CAP), intraabdominal infections (IAI) or primary bacteremia (BSI) and at least two signs of the systemic inflammatory response syndrome were analyzed. The study primary endpoint was to define how comorbidities as expressed in the Charlson’s comorbidity index (CCI) and the underlying type of infection contribute to development of organ dysfunction. The precise comorbidities that mediate sepsis development and risk for death among 18 comorbidities recorded were the secondary study endpoints. CCI more than 2 had an odds ratio of 5.67 for sepsis progression in patients with IAI between significantly higher than AP and BSI. Forward logistic regression analysis indicated seven comorbidities that determine transition into sepsis in patients with AP, four comorbidities in CAP, six comorbidities in IAI and one in BSI. The odds ratio both for progression to sepsis and death with one comorbidity or with two and more comorbidities was greater than in the absence of comorbidities. The study described how different kinds of infection vary in the degree to which they lead to sepsis. The number of comorbidities that enhances the risk of sepsis and death varies depending on the underlying infections.